Zai Lab Ltd.
Latest From Zai Lab Ltd.
Oncology continues to dominate new drug approvals in China as AstraZeneca gains the first clearance for a PD-L1 drug ahead of Roche. But there are as many as seven others in the class coming along, including from domestic firms Hengrui and CStone.
Novartis and Roche will present alongside up-and-coming biotechs and microcaps.
Emerging Company Profile: Founded by former executives of China’s national innovation darling Betta Pharma, Beijing-based Jacobio is focused on novel oncology assets, led by a KRAS inhibitor that's set to begin Phase I and IIa studies in the US and China for solid tumors.
While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.
- Medical Devices
- Therapeutic Areas
- Immune Disorders
- Respiratory, Pulmonary
- ZAI Laboratory Inc.
- Parent & Subsidiaries
- Zai Lab Ltd.
- Senior Management
Samantha Du, PhD, Chmn. & CEO
Billy Cho, CFO
Jonathan Wang, SVP, Head, Bus. Dev.
William Liang, Chief Commercial Officer
Tao Fu, Pres. & COO
- Contact Info
Zai Lab Ltd.
Phone: 21 6163 2588
4560 Jinke Rd., Jinchuang Plaza Bldg. 1
Pudong, Shanghai, 201210
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.